Guangdong Biolight Meditech Co., Ltd. Class A

Guangdong Biolight Meditech Co., Ltd. Class A

SSZSE:300246
12.56
CNY
-0.27
(-2.10%)
-0.45EPS
4.09BMarket Cap
Apr 29Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.08
1.31
1.7
2.71
3.25
3.71
3.77
6.37
4.98
4.54
4.52
4.04
4.14
4.25
Basic EPS, GAAP
0.13
0.15
0.11
0.31
0.26
0.29
0.3
1.58
0.29
0.08
-0.25
-0.27
-0.26
-0.45
Free Cash Flow per Basic Share
0.05
-0.06
- -
0.03
0.13
-0.08
0.16
1.77
-0.38
-0.27
-0.35
-0.43
-0.29
- -
Dividend per Share
0.07
0.03
0.03
0.04
0.04
0.04
0.09
0.15
0.27
0.16
0.18
0.07
0.12
0.22
Book Value per Share
1.76
1.88
1.96
2.12
2.31
2.56
2.5
4.19
4.08
5.37
4.95
4.61
4.3
4.09
Tangible Book Value per Share
1.5
1.54
1.6
1.52
1.6
1.85
1.77
3.1
3.03
4.51
4.4
4.08
3.8
3.62
Basic Weighted Avg Shares
217
220
224
219
219
219
219
219
219
261
264
263
265
263
Sales/Revenue/Turnover
235
289
381
594
711
813
826
1,396
1,091
1,184
1,194
1,060
1,095
1,118
Operating Margin (%)
12.34
11.73
8.44
14.02
13.4
11.9
12.42
31.83
9.02
2.39
6.87
-2.88
-1.53
-2.03
Depreciation Expense
6
9
11
12
13
14
14
18
40
51
58
69
76
- -
Net Income, GAAP
29
34
24
67
58
64
65
346
64
22
-65
-71
-69
-118
Effective Tax Rate (%)
12.73
13.61
11.69
13.97
17.88
14.48
18.43
15.56
13.63
- -
- -
- -
- -
- -
Profit Margin (%)
12.32
11.7
6.29
11.3
8.09
7.89
7.83
24.8
5.85
1.87
-5.46
-6.74
-6.34
-10.52
Working Capital
280
259
286
241
229
274
233
471
333
732
601
658
473
360
LT Debt
- -
- -
- -
- -
- -
70
73
164
213
274
308
410
327
275
Total Equity
394
428
461
504
554
622
586
1,033
992
1,502
1,389
1,291
1,212
1,156
Return on Invested Capital (%)
7.05
7.67
4.83
14.66
12.96
12.22
10.1
34.85
5.05
- -
- -
- -
- -
- -
Return on Capital (%)
7.25
7.89
4.15
11.52
8.22
7.97
8.69
34.8
5.39
- -
- -
- -
- -
- -
Return on Common Equity (%)
7.66
8.49
5.7
15.04
11.87
12.03
11.66
47.24
7.04
1.92
-4.78
-5.65
-5.89
-10.2

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
419
413
222
LT Borrowings
222
207
253
LT Finance Leases
26
26
21
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
265
265
265
Market Capitalization
3,951
3,723
4,093

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,213
1,232
1,086
Cash, Cash Equivalents & STI
577
607
389
Accounts Receivable, Net
242
246
238
Inventories
312
301
302
Total Current Liabilities
830
855
727
Payables & Accruals
- -
- -
- -
ST Debt
419
413
222
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.88%
5.35%
-6.11%
Free Cash Flow
-48.26%
-23.09%
-31.51%
Net Income, GAAP
7.91%
-106.92%
-2.82%
Sales/Revenue/Turnover
14.04%
-4.08%
3.29%
Total Cash Common Dividend
27.28%
14.27%
73.92%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
267
270
271
253
1,060
2025
248
276
- -
302
1,095
2026
243
275
298
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
-0.02
-0.04
-0.22
-0.27
2025
0.05
-0.05
- -
-0.23
-0.26
2026
-0.03
-0.1
-0.08
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.03
0.03
-0.01
0.07
2025
0.01
0.01
- -
0.06
0.12
2026
0.01
0.01
0.13
- -
- -

Company Description

CEO
Jin Yuan Yan
Full Time Employees
1,242
Sector
Health technology
Industry
Medical specialties
Address
Biolight Technology Park Zhuhai GD China 519085
IPO Date
Jul 19, 2011
Website
blt.com.cn
Business
Guangdong Biolight Meditech Co., Ltd. (300246.SZ) engages in the research, manufacturing, and global distribution of medical devices and healthcare solutions. Founded in Zhuhai, China, in 1993, the company delivers patient monitoring and life support systems, including various monitors, ECG machines, and medical pumps. Its offerings also span comprehensive renal care products, such as hemodialysis equipment and consumables, alongside homecare and veterinary medical solutions. Biolight operates internationally, serving markets throughout Asia, Africa, Europe, North America, and Latin America.